Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.
The potential effect of moexipril, a new converting enzyme inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of warfarin has been investigated. Ten healthy male volunteers received in a randomised crossover fashion a single oral dose of 50 mg warfarin sodium alone and together with the first dose of 6 days of oral treatment with moexipril 15 mg o.d. Mean oral plasma clearance of (R)-warfarin was 175 ml.h-1 in the absence and 181 ml.h-1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml.h-1 and 249 ml.h-1. Apparent volume of distribution, peak plasma concentration, time to reach peak concentration and area under the plasma concentration-time curve both of (R)- and (S)-warfarin were not significantly affected. Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve. The results suggest that a clinically important interaction between moexipril and warfarin is unlikely to occur in patients treated with both drugs.
Van Hecken
A
A
Department of Pharmacology, School of Medicine, University of Leuven, Belgium.
Verbesselt
R
R
Depré
M
M
Tjandramaga
T B
TB
Angehrn
J
J
Cawello
W
W
De Schepper
P J
PJ
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D010314:Partial Thromboplastin Time; D011355:Prodrugs / Q000494:pharmacology*; D011517:Prothrombin Time; D044005:Tetrahydroisoquinolines; D014859:Warfarin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D007546:Isoquinolines; D011355:Prodrugs; D044005:Tetrahydroisoquinolines; D014859:Warfarin; C058302:moexipril